Status:
COMPLETED
Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT
Lead Sponsor:
Turku University Hospital
Conditions:
Glioma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some ...
Eligibility Criteria
Inclusion
- Age: 18 to 70 years old
- Language spoken: Finnish or Swedish
- Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
- Supratentorial malignant glioma based on MRI imaging
- Supratentorial recurrent glioma based on MRI and/or \[11C\]methionine PET imaging
- Patients must be able to understand the meaning of the study and sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff
Exclusion
- Any medical or psychiatric condition that compromises the subject´s ability to participate in the study
- Any other significant disease including liver or renal disease
- Pregnant or lactating women
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01460706
Start Date
October 1 2011
End Date
December 1 2013
Last Update
December 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku PET Centre, Turku University Hospital
Turku, Finland, FI-21100